Biliary Rhabdomyosarcoma in an 8-Year-Old Boy: Contrast-Enhanced CT Findings, Differential Diagnosis, and Multidisciplinary Management

 

Edited by ScholarGen MediAI Team

Executive Answer

Biliary rhabdomyosarcoma is a rare malignant soft-tissue tumor that can obstruct the bile ducts and present with progressive jaundice in children. A key diagnostic pattern is an enhancing solid mass centered on the hepatic hilum or extrahepatic biliary tree, accompanied by upstream intrahepatic bile duct dilatation. In this 8-year-old boy, contrast-enhanced CT demonstrated a heterogeneously enhancing hilar lesion, internal nonenhancing areas, moderate bilateral intrahepatic ductal dilatation, and displacement of the major portal vein branches, which remained patent. Histopathologic examination established the diagnosis. The principal clinical lesson is straightforward: biliary dilatation should trigger a search for its cause, particularly when an associated solid mass is present.

1. Why This Case Matters

Jaundice in a child usually prompts an evaluation for hepatocellular disease, hemolysis, medication-related liver injury, congenital biliary abnormalities, and other causes of cholestasis. Depending on the clinical presentation, choledochal cysts, biliary stones, and ascending cholangitis may also enter the differential diagnosis.

The diagnostic approach must change when imaging reveals not only dilated bile ducts but also a solid, enhancing lesion centered on the biliary tree.

Biliary rhabdomyosarcoma is uncommon, yet it is an important consideration in children with unexplained biliary obstruction. Its clinical presentation can resemble more familiar biliary disorders, and the resulting diagnostic challenge is particularly relevant when a lesion near the hepatic hilum distorts the normal anatomy of the bile ducts and adjacent vessels.

This case illustrates a broader principle in abdominal radiology: identifying an abnormality is only the first step. The radiologist must determine what is causing it, establish the lesion's anatomic origin, characterize its internal composition, assess its relationship to adjacent structures, and communicate findings that influence subsequent management.

2. Clinical Scenario and Key Findings

An 8-year-old boy presented with worsening jaundice. Contrast-enhanced abdominal CT demonstrated a lesion centered on the hepatic hilum and extending along the expected course of the common bile duct, common hepatic duct, and proximal right and left hepatic ducts.

The principal imaging findings were:

• A heterogeneously enhancing soft-tissue lesion centered on the hepatic hilum and biliary tree.

• Internal areas that did not demonstrate enhancement.

• Moderate dilatation of the right and left intrahepatic bile ducts.

• Displacement of the right and left major portal vein branches adjacent to the mass.

• Preserved patency of the major portal vein branches on the available CT images.

• Postsurgical absence of the gallbladder.

• Splenomegaly.

• A small amount of perihepatic ascites.

Histopathologic examination confirmed biliary rhabdomyosarcoma.

The available clinical information does not establish the precise duration of jaundice, laboratory values, exact tumor dimensions, histologic subtype, immunohistochemical profile, metastatic status, treatment received, or subsequent outcome. These details must remain separate from the documented findings rather than being inferred from the CT appearance.

The diagnostic significance lies in the combination of a solid hilar lesion, heterogeneous enhancement, bilateral upstream biliary dilatation, and displacement of major vascular structures. No single feature is specific for rhabdomyosarcoma, but together they support a neoplastic cause of biliary obstruction and make a simple congenital ductal dilatation an inadequate explanation.

3. Pathophysiology: How a Biliary Tumor Produces Jaundice

Bile flows from the liver through the intrahepatic ducts, right and left hepatic ducts, common hepatic duct, and common bile duct before entering the duodenum. A lesion that narrows or obstructs this pathway increases resistance to bile flow. The ducts upstream from the obstruction may consequently become dilated, while impaired bile excretion can produce conjugated hyperbilirubinemia and clinically apparent jaundice.

The sequence is:

Tumor formation → biliary narrowing or obstruction → impaired bile drainage → upstream ductal dilatation → cholestasis → jaundice.

Persistent obstruction may also contribute to pruritus, nutritional deterioration, impaired hepatic function, and susceptibility to infection. If bacterial infection develops in an obstructed biliary system, cholangitis can become a clinically urgent complication.

The hepatic hilum is particularly important because the right and left hepatic ducts, portal vein, and hepatic arterial structures occupy a compact anatomic region. A mass in this location can affect both hepatic drainage pathways and distort the vascular anatomy relevant to surgery or interventional procedures.

In this patient, moderate dilatation of both intrahepatic ductal systems is consistent with an obstruction affecting the hilar biliary confluence or adjacent ducts. The displacement of the portal vein branches indicates a substantial spatial relationship between the lesion and the portal venous structures.

However, displacement is not synonymous with invasion. Likewise, preserved vascular patency does not independently exclude microscopic or mural involvement. These distinctions matter when describing local tumor extent and evaluating potential treatment options.

4. Epidemiology and Clinical Presentation

Biliary rhabdomyosarcoma is a rare anatomic presentation of rhabdomyosarcoma in childhood. A 2021 systematic review and individual-patient-data meta-analysis evaluated 176 patients and reported that biliary rhabdomyosarcoma represents approximately 0.5%–1.5% of pediatric rhabdomyosarcoma cases. Estimates vary across publications, and the rarity of the disease limits the precision of epidemiologic comparisons.

The median age at diagnosis in that analysis was approximately 36 months. Jaundice was the most frequently reported presenting symptom, followed by abdominal pain and fever. Although many affected children are very young, an 8-year-old child remains within the possible clinical spectrum.

Jaundice is not a diagnosis. Its interpretation requires attention to the pattern of bilirubin elevation, liver enzymes, clinical history, and imaging findings. Dark urine, pale stools, pruritus, abdominal discomfort, fever, and reduced appetite may provide additional evidence of cholestasis or complications, but their presence or absence should be established from the individual history.

Laboratory assessment commonly includes total and direct bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, coagulation studies, and other tests guided by the clinical context. Fever, abdominal pain, and systemic deterioration warrant assessment for cholangitis or other acute complications.

Splenomegaly and a small amount of perihepatic ascites were also present on this patient's CT. These findings deserve clinical correlation, but neither finding alone establishes portal hypertension, chronic liver disease, or metastatic involvement.

5. Contrast-Enhanced CT: A Structured Radiologic Assessment

Contrast-enhanced CT is valuable for rapidly characterizing an abdominal mass, identifying the level of biliary obstruction, assessing enhancement, and mapping the relationship between the lesion and adjacent vessels and organs.

For a suspected hilar biliary tumor, the interpretation should address five questions:

1. Where is the lesion centered?

2. Is the abnormality predominantly solid, cystic, or intraductal?

3. What is the distribution of enhancement within the lesion?

4. How extensive is the upstream biliary dilatation?

5. Are the portal vein, hepatic arteries, liver parenchyma, and other adjacent structures displaced, narrowed, encased, or invaded?

Figure 1. Coronal Contrast-Enhanced CT, Portal Venous Phase

Image interpretation: The coronal portal venous phase CT demonstrates a heterogeneously enhancing lesion centered on the hepatic hilum along the course of the biliary tree, accompanied by moderate dilatation of both intrahepatic ductal systems.

Diagnostic significance: Coronal images help establish the longitudinal distribution of the lesion and the extent of upstream ductal dilatation. They are particularly useful for understanding how a hilar process relates to the right and left hepatic ducts.

Clinical implication: The combination of a hilar mass and bilateral ductal dilatation should prompt a focused assessment of the biliary confluence and the structures that may influence surgical planning. MRI and magnetic resonance cholangiopancreatography (MRCP) can provide additional anatomic detail when clinically appropriate.

ALT text: Coronal contrast-enhanced CT showing a heterogeneous hilar mass with bilateral intrahepatic bile duct dilatation in a child with biliary rhabdomyosarcoma.

Figure 2. Axial Contrast-Enhanced CT, Arterial Phase

Image interpretation: The arterial phase image is used to evaluate the enhancement characteristics of the hilar lesion and its spatial relationship to adjacent vascular structures.

Diagnostic significance: Arterial phase enhancement contributes to assessment of lesion heterogeneity and vascular relationships. However, enhancement patterns overlap among different neoplasms and cannot establish the histologic diagnosis of rhabdomyosarcoma.

Clinical implication: The hepatic hilum contains closely related biliary, portal venous, and arterial structures. A report should distinguish simple contact or displacement from findings that suggest encasement, narrowing, or invasion. The presence of an adjacent vessel does not, by itself, establish vascular invasion.

ALT text: Axial arterial phase contrast-enhanced CT for assessment of a hilar biliary mass and its relationship to adjacent vessels.

Figure 3. Axial Contrast-Enhanced CT, Delayed Phase

Image interpretation: The delayed phase image allows assessment of the lesion's enhancement distribution over time, including internal regions that remain nonenhancing.

Diagnostic significance: The nonenhancing areas indicate internal heterogeneity. They should not automatically be labeled necrosis, hemorrhage, or another specific tissue component without supporting evidence from additional imaging or pathology.

Clinical implication: Comparing arterial, portal venous, and delayed phase images can improve characterization of the lesion and its interface with adjacent structures. The interpretation should describe what is observed before proposing an explanation for the nonenhancing components.

ALT text: Axial delayed phase contrast-enhanced CT demonstrating heterogeneous enhancement and internal nonenhancing regions within a hilar biliary lesion.

Figure 4. Axial Contrast-Enhanced CT, Portal Venous Phase

Image interpretation: The portal venous phase image demonstrates the relationship between the hilar mass and the main portal vein and its major branches. The major portal vein branches are displaced but remain patent on the available images. Bilateral intrahepatic bile duct dilatation is also present.

Diagnostic significance: Vascular displacement and luminal patency are important observations, but they do not definitively exclude vascular wall involvement. The degree of contact, contour irregularity, luminal narrowing, and any encasement should be evaluated in the complete imaging examination.

Clinical implication: Portal venous anatomy can influence surgical feasibility and the selection of subsequent diagnostic or therapeutic procedures. Multiplanar CT and MRI may provide additional information for treatment planning.

ALT text: Axial portal venous phase CT showing displacement of patent major portal vein branches adjacent to a hilar biliary mass.

6. MRI and MRCP: Defining the Biliary Anatomy

MRI provides soft-tissue contrast that can complement CT when evaluating a hilar mass and its relationship to the liver and biliary structures. MRCP uses heavily T2-weighted sequences to depict fluid-containing bile ducts and can help define the level and longitudinal extent of obstruction, the configuration of the hepatic duct confluence, and the continuity of the biliary system.

Diffusion-weighted imaging and apparent diffusion coefficient maps may contribute additional information about tissue characteristics. Restricted diffusion, however, is not specific to malignancy and cannot substitute for histopathologic diagnosis.

MRI and MRCP can be particularly useful when the extent of biliary involvement remains uncertain after CT or when detailed anatomic mapping is required for procedural planning. In children, the choice and timing of MRI should account for clinical urgency, examination duration, motion, and the potential need for sedation.

The imaging strategy should be complementary rather than repetitive: ultrasound can establish ductal dilatation, CT can rapidly characterize the mass and its vascular relationships, and MRI/MRCP can clarify biliary anatomy where additional detail is likely to change management.

7. Differential Diagnosis: What Else Can Mimic Biliary Rhabdomyosarcoma?

Choledochal cyst

A choledochal cyst is an important consideration in a child with biliary dilatation. Its defining feature is abnormal cystic dilatation of the biliary tree rather than an enhancing solid mass causing obstruction.

The distinction is not always straightforward on an initial examination. A lesion that appears fluid-filled or dilated should be assessed for internal soft tissue, irregular wall thickening, an associated mass, and the distribution of ducts upstream from the suspected obstruction.

Practical point: Do not classify unexplained biliary dilatation as a congenital cyst without evaluating whether a solid lesion accounts for the abnormal anatomy.

Biliary stones and sludge

Stones may cause ductal obstruction and upstream dilatation. Depending on composition, they can appear as filling defects or intraductal material, with variable CT attenuation. Ultrasound may demonstrate shadowing in appropriate circumstances.

A stone or sludge finding should not end the evaluation if a separate enhancing soft-tissue mass remains unexplained. The presence of one potential cause of obstruction does not automatically account for every imaging abnormality.

Cholangitis

Cholangitis may develop in the setting of obstruction and infection. Fever, abdominal pain, jaundice, inflammatory marker elevation, and systemic illness may support the diagnosis.

However, cholangitis describes an inflammatory or infectious process; it does not necessarily identify the underlying cause of obstruction. A tumor may obstruct the ducts and predispose the patient to secondary infection. Clinical stabilization and evaluation of the obstructing lesion may therefore need to proceed in parallel.

Other hilar masses and malignancies

Other tumors arising from the liver, biliary structures, or surrounding tissues can produce hilar obstruction. Enlarged lymph nodes and other soft-tissue masses may also distort the biliary anatomy.

The key radiologic question is whether the lesion is centered within the ductal lumen, involves the duct wall, arises in the adjacent liver, or originates from surrounding soft tissues or lymph nodes. Enhancement and vascular relationships can narrow the differential, but they do not reliably distinguish all tumor types.

The final diagnosis of biliary rhabdomyosarcoma requires tissue confirmation.

8. Pathology: Establishing the Diagnosis

Imaging establishes the location, extent, and structural consequences of a lesion; pathology establishes its histologic identity.

Rhabdomyosarcoma is a malignant neoplasm characterized by skeletal muscle differentiation. Embryonal histology is frequently reported in pediatric biliary rhabdomyosarcoma, and a botryoid growth pattern may occur in some cases. These general patterns must not be assigned to an individual patient without the corresponding pathology findings.

Histopathologic evaluation is interpreted alongside immunohistochemistry. Desmin, myogenin, and MyoD1 are commonly used markers in the diagnostic assessment of rhabdomyosarcoma. The panel must be interpreted in the context of morphology and the broader differential diagnosis rather than relying on a single marker in isolation.

Molecular testing may be appropriate when required for classification, risk assessment, or treatment planning. The specific studies depend on the pathologic findings and the clinical protocol.

In this case, histopathology confirmed biliary rhabdomyosarcoma. The precise histologic subtype, immunohistochemical results, and molecular findings are not reported in the available clinical information and should not be inferred from the CT images.

9. Treatment: Coordinating Tumor Control and Biliary Management

Treatment of pediatric biliary rhabdomyosarcoma requires an individualized, multidisciplinary strategy. Relevant variables include tumor extent, histologic and molecular classification, regional lymph node involvement, distant metastatic disease, vascular and biliary anatomy, resectability, organ function, and anticipated treatment response.

Because this is a rare tumor, evidence specific to biliary rhabdomyosarcoma is limited compared with evidence for pediatric rhabdomyosarcoma overall. Management decisions should be guided by an experienced pediatric oncology team using the applicable treatment protocol and the available evidence.

Initial stabilization and biliary drainage

The initial assessment should establish the severity of cholestasis, hepatic dysfunction, coagulation abnormalities, nutritional compromise, and any evidence of infection.

When clinically indicated, biliary drainage may be considered through an appropriate endoscopic, percutaneous, or surgical approach. The choice depends on the level of obstruction, the anatomy of the biliary tree, infection status, technical feasibility, and the anticipated definitive treatment.

Drainage is not automatically required for every patient. Its purpose and timing should be determined by the clinical condition and the overall treatment plan.

Systemic chemotherapy

Chemotherapy is a central component of treatment for many pediatric rhabdomyosarcomas. Depending on the applicable protocol and risk classification, regimens may include combinations of vincristine, dactinomycin, and cyclophosphamide. The actual regimen, doses, schedule, and use of additional agents must be selected by the treating pediatric oncology team.

Systemic therapy may reduce tumor burden, help control microscopic disease, and influence whether subsequent surgery is feasible. Treatment response should be assessed using clinical findings, laboratory data, and appropriately selected follow-up imaging.

Surgery and local control

Surgical resection can have an important role, but immediate extensive surgery is not necessarily the optimal first step for every hilar tumor.

The portal vein, hepatic arteries, and major bile ducts are closely packed at the hepatic hilum. Attempting resection without careful assessment may carry substantial risks to vascular integrity, biliary drainage, and liver function.

Planning should consider whether complete resection is feasible, the extent of biliary involvement, the relationship to major vessels, the volume and function of the remaining liver, the response to chemotherapy, and the morbidity of the proposed procedure.

The 2021 systematic review reported an association between the absence of surgical resection and poorer outcomes in the analyzed population. This observation should not be interpreted as proof that every patient should undergo immediate surgery. Selection factors, tumor extent, treatment era, and individual clinical circumstances affect the interpretation of retrospective evidence.

In selected patients, systemic therapy followed by reassessment may inform the timing and extent of surgery.

Radiation therapy

Radiation therapy may be considered according to tumor risk, disease extent, surgical margins, histology, and the applicable protocol. The potential benefit of local control must be weighed against the risk of late effects in a developing child.

The proximity of the liver, gastrointestinal tract, bile ducts, and major vessels makes careful treatment planning particularly important. Radiation therapy is not automatically required for every patient.

Treatment costs and resource utilization

The cost of care varies with treatment duration, hospitalization, imaging, drainage procedures, surgery, chemotherapy, radiation therapy, complications, and long-term follow-up. Insurance coverage and healthcare systems also influence total expenditure.

A single standardized cost estimate would be misleading without a defined treatment pathway and healthcare setting. From a healthcare systems perspective, timely diagnosis may help avoid unnecessary diagnostic repetition and support coordinated treatment planning, although the financial impact for an individual case cannot be quantified from the available information.

10. Prognosis: Interpreting Population Data Carefully

The prognosis of biliary rhabdomyosarcoma depends on disease extent, metastatic status, histologic and molecular characteristics, treatment response, and the feasibility of achieving effective local control.

The 2021 systematic review and individual-patient-data meta-analysis of 176 patients reported an overall 5-year survival rate of approximately 51% and a 5-year progression-free survival rate of approximately 50%. Among patients treated from 2000 onward, the reported estimates were approximately 65% for 5-year overall survival and 59% for 5-year progression-free survival.

These estimates describe the study populations; they are not individualized predictions. The small number of patients, differences in treatment protocols, and changes in clinical practice over time limit direct comparisons across groups.

For this 8-year-old boy, the imaging findings and histopathologic diagnosis alone do not establish stage, risk group, response to treatment, or prognosis. The metastatic evaluation, pathology details, and subsequent clinical course are not reported in the available clinical information.

Long-term follow-up in pediatric patients should consider disease recurrence, biliary complications, liver function, nutrition, growth, and potential late effects of treatment.

11. Diagnostic Risk: Why the Mass Can Be Missed

The most consequential perceptual error in this setting is to recognize biliary dilatation but fail to identify the lesion causing it.

Several factors can contribute to this risk:

• Anchoring on a common diagnosis: A congenital biliary abnormality may be considered before the entire ductal anatomy and any associated soft tissue have been assessed.

• Satisfaction of search: Once dilated ducts are identified, the reader may stop looking for an obstructing mass.

• Incomplete characterization: A report may describe enhancement without documenting the lesion's center, upstream ductal distribution, or vascular relationships.

• Overinterpretation of a single feature: A nonenhancing component may be labeled necrosis without sufficient evidence, or patent vessels may be taken to exclude invasion.

• Fragmented communication: Imaging findings may not be integrated promptly with pathology, pediatric oncology, surgery, and the need to evaluate biliary complications.

These are system-level vulnerabilities, not evidence of an error by any particular clinician. A structured interpretation framework can improve consistency, particularly when the disease is rare, and the initial presentation resembles a more common condition.

12. Can Artificial Intelligence Help Identify Rare Biliary Tumors?

Artificial intelligence (AI) may support abdominal imaging workflows, but its role in a rare tumor such as biliary rhabdomyosarcoma must be defined realistically.

Potentially useful functions include automated identification of biliary dilatation, detection of abdominal masses, segmentation of liver and vascular structures, measurement of lesion dimensions, and comparison of serial examinations. These functions could help direct attention to an abnormality that warrants further evaluation.

However, detecting an abnormality is not the same as identifying its histology. A model trained primarily on common abdominal diseases may not reliably classify an exceptionally rare pediatric tumor. Even a system that detects a hilar mass may not distinguish rhabdomyosarcoma from a choledochal cyst with atypical features, another malignancy, inflammatory disease, or other causes of obstruction.

Several limitations are especially relevant:

• False negatives: A subtle or atypical lesion may not trigger an alert.

• False positives: Benign or unrelated findings may generate unnecessary notifications.

• Dataset bias: Rare pediatric tumors may be inadequately represented in training and validation data.

• Domain shift: Performance may change across scanners, institutions, protocols, and patient populations.

• Image quality and protocol variation: Motion, contrast timing, and acquisition differences can affect model output.

• Alert fatigue: Excessive notifications may reduce attention to clinically important findings.

• Lack of histologic specificity: Imaging AI cannot independently establish the tissue diagnosis.

No AI performance metrics or validated biliary rhabdomyosarcoma detection system are established by this case. It would therefore be inappropriate to claim a specific level of accuracy or to suggest that AI can diagnose this tumor from CT alone.

A practical AI-assisted workflow

A clinically responsible workflow could use AI to flag a combination of biliary dilatation and a suspected hilar mass, while leaving interpretation and decision-making to the radiologist and treating team.

1. The imaging study enters the hospital's established PACS workflow.

2. An appropriately validated tool, if available, flags a potential mass or abnormal ductal dilatation.

3. The radiologist reviews the complete examination, including the source images and relevant multiplanar reconstructions.

4. The radiologist documents the lesion's location, enhancement pattern, upstream ductal dilatation, and relationship to major vessels.

5. Clinically significant findings are communicated to the treating team, with appropriate urgency based on the patient's condition.

6. MRI/MRCP, pathology, staging, and multidisciplinary review are arranged as indicated.

7. Follow-up examinations are compared with baseline imaging to assess treatment response.

Implementation requires local validation, integration with PACS and the electronic health record, appropriate alert routing, monitoring for false positives and false negatives, and clear assignment of clinical responsibility. AI should support attention and workflow, not replace professional interpretation.

13. A Practical Diagnostic Algorithm

For a child with progressive jaundice and suspected biliary obstruction, the following sequence provides a structured approach:

Step 1 — Establish the clinical context. Assess symptom progression, direct and total bilirubin, liver enzymes, coagulation, nutritional status, and evidence of infection.

Step 2 — Evaluate the biliary tree. Use ultrasound as an initial examination when appropriate to identify ductal dilatation, gallbladder status, and a possible obstructing lesion.

Step 3 — Characterize the suspected mass. Contrast-enhanced CT can define the lesion's location, enhancement, internal heterogeneity, upstream ductal dilatation, and relationship to adjacent vessels and organs.

Step 4 — Clarify ductal anatomy. MRI/MRCP can help delineate the level and extent of biliary involvement when additional detail will influence management.

Step 5 — Establish the tissue diagnosis. Histopathology and appropriate immunohistochemical studies are necessary to confirm rhabdomyosarcoma and distinguish it from other tumors.

Step 6 — Determine disease extent. Complete staging and risk assessment should be performed according to the pediatric oncology protocol.

Step 7 — Coordinate treatment. Pediatric oncology, radiology, pathology, pediatric surgery, hepatobiliary surgery, and radiation oncology should contribute as appropriate.

Step 8 — Monitor response and complications. Integrate symptoms, laboratory findings, follow-up imaging, and long-term surveillance.

The exact order and timing of investigations may change when urgent biliary decompression, infection management, or another clinical priority takes precedence.

14. Practical Radiology Pearls

• In a child with unexplained jaundice, biliary dilatation requires evaluation of its underlying cause.

• A solid, enhancing lesion along the biliary tree should prompt consideration of neoplastic obstruction, including rare pediatric tumors.

• Bilateral intrahepatic ductal dilatation can indicate obstruction at or near the hepatic hilum.

• Heterogeneous enhancement and internal nonenhancing areas should be described accurately without assigning an unsupported tissue diagnosis.

• Portal vein displacement and preserved luminal patency are important findings, but they do not definitively exclude vascular invasion.

• CT is valuable for mass characterization and vascular mapping; MRI/MRCP can clarify biliary anatomy.

• Imaging can suggest a tumor but cannot establish the histologic subtype of rhabdomyosarcoma.

• Treatment planning should integrate staging, pathology, vascular and biliary anatomy, resectability, and response to systemic therapy.

• AI may help identify abnormalities, but rare-tumor diagnosis requires human review and pathologic confirmation.

15. Frequently Asked Questions

What are the key CT findings of biliary rhabdomyosarcoma?

The key findings may include a solid soft-tissue mass involving the extrahepatic biliary tree or hepatic hilum, heterogeneous enhancement, upstream intrahepatic bile duct dilatation, and displacement of adjacent vascular structures. These findings raise suspicion but are not specific enough to establish the diagnosis without tissue confirmation.

Can biliary rhabdomyosarcoma be mistaken for a choledochal cyst?

Yes. Both conditions may be encountered during the evaluation of biliary dilatation in children. Careful assessment for a solid enhancing component, irregular tissue, and an obstructing mass helps distinguish a neoplastic process from a primarily cystic ductal abnormality.

Does a patent portal vein exclude tumor invasion?

No. Patency indicates that the vessel lumen remains open on the examined images. The radiologist must also evaluate the vessel contour, degree of contact, narrowing, encasement, and other signs of involvement. Imaging findings should be interpreted together rather than using luminal patency as a definitive exclusion criterion.

Is CT sufficient to diagnose biliary rhabdomyosarcoma?

No. CT can characterize the lesion and help define its anatomic extent, but the histologic diagnosis requires tissue examination. Immunohistochemistry and, when appropriate, molecular testing contribute to tumor classification.

What is the role of MRI and MRCP?

MRI provides additional soft-tissue characterization, while MRCP depicts the biliary anatomy and can help define the level and extent of ductal involvement. Their use depends on clinical urgency, the information already available from CT, and whether additional findings could influence treatment planning.

What treatment is used for pediatric biliary rhabdomyosarcoma?

Treatment is individualized and may combine systemic chemotherapy, surgery, and selected radiation therapy. Biliary drainage may be necessary in specific clinical circumstances. The treatment sequence depends on the tumor's extent, histology, resectability, complications, and response to therapy.

Can AI independently identify this rare tumor?

AI may help flag a mass or biliary dilatation, but reliable identification of a rare histologic subtype cannot be assumed. Model validation, human interpretation, clinical correlation, and tissue diagnosis remain essential.

Quiz

Question 1. A child has progressive jaundice, bilateral intrahepatic ductal dilatation, and a solid enhancing hilar mass. What is the most appropriate diagnostic principle?

A. Biliary dilatation alone establishes a choledochal cyst.
B. The mass should be characterized and the cause of obstruction investigated.
C. Enhancement establishes rhabdomyosarcoma.
D. Tissue diagnosis is unnecessary if CT is characteristic.

Correct answer: B. Biliary dilatation is a finding, not an etiologic diagnosis. The obstructing lesion must be characterized, and tissue confirmation is required when malignancy is suspected.

Question 2. CT shows displacement of the major portal vein branches, with preserved luminal patency. Which interpretation is most appropriate?

A. Vascular invasion is completely excluded.
B. Portal vein thrombosis is established.
C. The vessels are displaced but patent; invasion requires a broader assessment.
D. The finding has no relevance to treatment planning.

Correct answer: C. Vascular displacement and luminal patency should be documented separately. Vessel morphology and the tumor–vessel interface must also be considered.

Question 3. What is the most appropriate approach after biliary rhabdomyosarcoma is confirmed histologically?

A. Immediate extensive surgery in every patient.
B. Chemotherapy alone for every patient.
C. Individualized staging and multidisciplinary treatment planning.
D. Observation based solely on internal nonenhancing areas.

Correct answer: C. Treatment must account for disease extent, tumor biology, resectability, response to systemic therapy, and the risks of local treatment.

Conclusion: Find the Cause of the Dilated Ducts

Biliary rhabdomyosarcoma is rare, but it belongs in the differential diagnosis when a child presents with progressive jaundice and imaging demonstrates biliary obstruction associated with a solid mass.

In this 8-year-old boy, contrast-enhanced CT showed a heterogeneous hilar lesion with internal nonenhancing areas, moderate bilateral intrahepatic ductal dilatation, and displacement of major portal vein branches that remained patent. Histopathologic examination confirmed biliary rhabdomyosarcoma.

The essential radiologic lesson is to move beyond the observation of dilated ducts. A careful assessment of the obstructing lesion, enhancement pattern, ductal distribution, and relationship to adjacent vessels can provide the information needed for further diagnostic evaluation and treatment planning.

CT and MRI/MRCP offer complementary anatomic information, while pathology establishes the diagnosis. Multidisciplinary management integrates staging, systemic therapy, surgery, and selected local treatments according to the individual patient's circumstances.

For rare pediatric tumors, diagnostic quality depends not on recognizing every disease from a single image, but on identifying the right pattern, maintaining an appropriate differential diagnosis, communicating uncertainty, and ensuring that the next clinical decision follows from the evidence.

References

1. Fuchs JF, et al. Biliary Rhabdomyosarcoma in Pediatric Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. Frontiers in Oncology. 2021. https://doi.org/10.3389/fonc.2021.701400

2. Alpin DM, Fernandez-Pineda I. The Evolution of Diagnosis and Management of Pediatric Biliary Tract Rhabdomyosarcoma. Current Pediatric Reviews. 2016;12(3). https://doi.org/10.2174/1573396312666160118104903

3. Tripathy TP, et al. Embryonal Rhabdomyosarcoma of the Biliary Tree as a Differential in a Paediatric Patient Presenting with Biliary Dilatation: Not Always a Choledochal Cyst. Acta Medica Lituanica. 2022;29(1):112–117. https://doi.org/10.15388/Amed.2021.29.1.2

4. Święszkowska E, et al. Rhabdomyosarcoma of the Biliary Tract in Children: Analysis of Single Center Experience. Cancers. 2024;16(17):3110. https://doi.org/10.3390/cancers16173110

5. Huang T, et al. Multimodality Imaging in the Diagnosis of Biliary Rhabdomyosarcoma in a Young Child: A Case Report. Frontiers in Pediatrics. 2026;14:1852972. https://doi.org/10.3389/fped.2026.1852972

6. Hawkins DS, et al. The Children's Oncology Group's 2022 Blueprint for Research: Soft Tissue Sarcomas. Pediatric Blood & Cancer. 2022.

7. National Cancer Institute. Childhood Rhabdomyosarcoma Treatment (PDQ®)–Health Professional Version. https://www.cancer.gov/types/soft-tissue-sarcoma/hp/rhabdomyosarcoma-treatment-pdq

8. World Health Organization. WHO Classification of Tumours: Soft Tissue and Bone Tumours. 5th ed. International Agency for Research on Cancer; 2020.

Continue Learning

Abdominal Imaging and Biliary Disease

• Pediatric Jaundice: A Radiologic Approach to Biliary Obstruction — [INTERNAL LINK PLACEHOLDER]

• Choledochal Cysts: Imaging Features and Differential Diagnosis — [INTERNAL LINK PLACEHOLDER]

• MRI and MRCP in the Assessment of Biliary Obstruction — [INTERNAL LINK PLACEHOLDER]

Medical Disclaimer

This article is intended for medical education and professional information. It does not replace individualized medical assessment, diagnosis, or treatment. Clinical decisions should be made by qualified healthcare professionals using the complete clinical record and applicable institutional protocols.